sellWeak cluster of 610b5-1 plan
Rolph Timothy sold $118k of AKRO
Chief Scientific Officer at Akero Therapeutics, Inc.. 3,800 shares at an average of $31.10, traded Dec 17, 2024, filed Dec 18, 2024.
Warning score
5Value
$118k
3,800 shares
Holdings after
178,337
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-138134, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | MOption exercise Common Stock10b5-1 | +3,800 | $19.87 | $76k | 182,137 | Dec 18, 2024 |
| Dec 17, 2024 | SOpen-market sale Common Stock10b5-1 | -3,800 | $31.10 | $118k | 178,337 | Dec 18, 2024 |
| Dec 16, 2024 | AGrant or award Common Stock10b5-1 | +20,000 | $0.00 | $0 | 198,337 | Dec 18, 2024 |
| Dec 17, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,800 | $0.00 | $0 | 134,955 | Dec 18, 2024 |
| Dec 16, 2024 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +60,000 | $0.00 | $0 | 60,000 | Dec 18, 2024 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 8Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Yale Catriona Chief Development Officer | $264k | 9,074 | |
| 15Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Lamy Patrick Senior VP, Commercial Strategy | $29k | 1,000 | |
| 53Moderate | sell 6 | AKRO Akero Therapeutics, Inc. | Cheng Andrew President and CEO | $242k | 7,855 | |
| 46Moderate | sell 6 | AKRO Akero Therapeutics, Inc. | White William Richard Chief Financial Officer | $87k | 2,817 | |
| 39Weak | sell 6 | AKRO Akero Therapeutics, Inc. | Yale Catriona Chief Development Officer | $87k | 2,810 | |
| 35Weak | sell 6 | AKRO Akero Therapeutics, Inc. | Lamy Patrick Senior VP, Commercial Strategy | $28k | 925 | |
| 43Moderate | sell 6 | AKRO Akero Therapeutics, Inc. | Young Jonathan Chief Operating Officer | $77k | 2,503 | |
| 6Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Rolph Timothy Chief Scientific Officer | $149k | 4,818 | |
| 29Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Young Jonathan Chief Operating Officer | $321k | 10,000 | |
| 27Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Cheng Andrew President and CEO | $802k | 25,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.